CBT 102
Latest Information Update: 17 May 2024
At a glance
- Originator CERES BRAIN Therapeutics
- Class Acetates; Urea compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 24 Apr 2024 Preclinical trials in Parkinson's disease in France (unspecified route) (Ceres Brain therapeutics pipeline, April 2024)
- 24 Apr 2024 Ceres Brain therapeutics plans a clinical trial for Parkinson's disease (Ceres Brain therapeutics pipeline, April 2024)